This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Candesartan cilexetil

Read time: 1 mins
Marketing start date: 23 Nov 2024
...
 

Summary of product characteristics


Effective Time

20221013

Version

4

Spl Product Data Elements

Candesartan cilexetil Candesartan cilexetil CANDESARTAN CILEXETIL CANDESARTAN CARBOXYMETHYLCELLULOSE CALCIUM FERRIC OXIDE RED HYDROXYPROPYL CELLULOSE (110000 WAMW) LACTOSE MONOHYDRATE MAGNESIUM STEARATE POLYETHYLENE GLYCOL 6000 STARCH, CORN LIGHT PINK ROUND ZE;58 Candesartan cilexetil Candesartan cilexetil CANDESARTAN CILEXETIL CANDESARTAN CARBOXYMETHYLCELLULOSE CALCIUM FERRIC OXIDE RED HYDROXYPROPYL CELLULOSE (110000 WAMW) LACTOSE MONOHYDRATE MAGNESIUM STEARATE POLYETHYLENE GLYCOL 6000 STARCH, CORN PINK ROUND ZE;59 Candesartan cilexetil Candesartan cilexetil CANDESARTAN CILEXETIL CANDESARTAN CARBOXYMETHYLCELLULOSE CALCIUM HYDROXYPROPYL CELLULOSE (110000 WAMW) LACTOSE MONOHYDRATE MAGNESIUM STEARATE POLYETHYLENE GLYCOL 6000 STARCH, CORN WHITE ROUND ZE;60 Candesartan cilexetil Candesartan cilexetil CANDESARTAN CILEXETIL CANDESARTAN CARBOXYMETHYLCELLULOSE CALCIUM HYDROXYPROPYL CELLULOSE (110000 WAMW) LACTOSE MONOHYDRATE MAGNESIUM STEARATE POLYETHYLENE GLYCOL 6000 STARCH, CORN WHITE TO OFF-WHITE ROUND ZE;61

Application Number

ANDA091390

Brand Name

Candesartan cilexetil

Generic Name

Candesartan cilexetil

Product Ndc

70771-1206

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1204-5 Candesartan Cilexetil Tablets USP, 4 mg Rx Only 500 tablets NDC 70771-1205-5 Candesartan Cilexetil Tablets USP, 8 mg Rx Only 500 tablets NDC 70771-1206-5 Candesartan Cilexetil Tablets USP, 16 mg Rx Only 500 tablets NDC 70771-1207-5 Candesartan Cilexetil Tablets USP, 32 mg Rx Only 500 tablets labels labels labels labels

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.